Correlation of the expression of vascular endothelial growth factor and its receptors with microvessel density in ovarian cancer

Wang,Limei; Liu,Xiaoyan; Wang,Hong; Wang,Shuhe

doi:10.3892/ol.2013.1349

Correlation of the expression of vascular endothelial growth factor and its receptors with microvessel density in ovarian cancer

Authors:
- Limei Wang
- Xiaoyan Liu
- Hong Wang
- Shuhe Wang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Beijing General Army Hospital, Beijing 100700, P.R. China, Department of Medical Record Management, Beijing General Army Hospital, Beijing 100700, P.R. China, Department of Ultrasound, Beijing General Army Hospital, Beijing 100700, P.R. China
Published online on: May 15, 2013 https://doi.org/10.3892/ol.2013.1349
Pages: 175-180

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the correlation between the expression of vascular endothelial growth factor (VEGF) and its receptors, the Flt‑1 and KDR proteins, with clinical pathology and microvessel density (MVD) in ovarian cancer tissue. The protein expression levels of VEGF and its receptors, Flt‑1 and KDR/Flk‑1, were detected in 48 cases of ovarian cancer using the streptavidin‑biotin complex (SABC) immunohistochemical method, and tumor MVD was evaluated using F8 factor (FVIII‑RA). The expression of the VEGF, Flt‑1 and KDR proteins was not significantly associated with the pathological type, extent of differentiation or clinical stage of ovarian cancer. However, the co-expression of VEGF and Flt‑1 was markedly correlated with differentiation and clinical stage (P<0.01). The co-expression levels of VEGF and receptor Flt‑1 in malignant neoplasms with lymph node metastasis was significantly higher compared with malignant neoplasms without lymph node metastasis (P<0.05). The expression level of KDR in patients with hepatic metastasis was significantly higher compared with patients without hepatic metastasis (P<0.05). The co-expression level of VEGF and KDR in patients with hepatic metastasis was significantly higher compared with patients without hepatic metastasis (P<0.05) and the Flt‑1 expression level in patients with ascites <1,000 ml was significantly lower than that in patients with ascites ≥1000 ml (P<0.05). The mean MVD of VEGF‑ and KDR‑positive patients was significantly higher compared with VEGF‑ and KDR‑negative patients (P<0.05). The expression of VEGF and its receptors is involved in the malignant transformation of ovarian tumors, tumor progression and metastasis, as well as ascites formation and angiogenesis.

View Figures

View References

1.	Nsihida N, Yano H, Komai K, Nishida T, Kamura T and Kojiro M: Vascular endothelial growth factor-C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer. 101:1364–1374. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E and Pavlidis N: Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma. Int J Gynecol Cancer. 16(Suppl 1): 241–246. 2006. View Article : Google Scholar
3.	Gómez-Raposo C, Mendiola M, Barriuso J, Casado E, Hardisson D and Redondo A: Angiogenesis and ovarian cancer. Clin Transl Oncol. 11:564–571. 2009.
4.	Diniz Bizzo SM, Meira DD, Lima JM, Mororó Jda S, Casali-da-Rocha JC and Ornellas MH: Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer. Int J Gynaecol Obstet. 109:113–117. 2010.PubMed/NCBI
5.	Hefler LA, Zeillinger R, Grimm C, et al: Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 103:512–517. 2006. View Article : Google Scholar : PubMed/NCBI
6.	Zhao Y, Zong ZH and Xu HM: RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9. Gynecol Oncol. 116:563–571. 2010. View Article : Google Scholar
7.	Weidner N, Folkman J, Pozza F, et al: Tumor angiogensis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Cancer Inst. 84:1875–1887. 1992. View Article : Google Scholar : PubMed/NCBI
8.	Brustmann H: Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with topoisomerase II alpha and prognosis. Gynecol Oncol. 95:16–22. 2004. View Article : Google Scholar
9.	Mabuchi S, Kawase C, Altomare DA, et al: Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary. Mol Cancer Ther. 9:2411–2422. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Smerdel MP, Waldstrøm M, Brandslund I, Steffensen KD, Andersen RF and Jakobsen A: Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer. 19:578–584. 2009. View Article : Google Scholar
11.	Verheul HM, Hoekman K, Jorna AS, Smit EF and Pinedo HM: Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist. 5:45–50. 2000. View Article : Google Scholar : PubMed/NCBI
12.	Shen GH, Ghazizadeh M, Kawanami O, et al: Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer. 83:196–203. 2000.PubMed/NCBI
13.	Herr D, Sallmann A, Bekes I, et al: VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5. Gynecol Oncol. 127:210–216. 2012. View Article : Google Scholar : PubMed/NCBI
14.	Rudlowski C, Pickart AK, Fuhljahn C, et al: Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer. 16(Suppl 1): 183–189. 2006. View Article : Google Scholar : PubMed/NCBI
15.	Fujimoto J, Sakaguchi H, Aoki I, Khatun S and Tamaya T: Clinical implications of expression of vascular endothelial growth factor in metastatic lesions of ovarian carcers. Br J Cancer. 85:313–316. 2001. View Article : Google Scholar : PubMed/NCBI
16.	Bolat F, Gumurdulu D, Erkanli S, et al: Maspin overexpression correlates with increased expression of vascular endothelial growth factors A, C and D in human ovarian carcinoma. Pathol Res Pract. 1:379–387. 2008. View Article : Google Scholar
17.	Shalaby F, Rossant J, Yamaguchi TP, et al: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature. 376:62–66. 1995. View Article : Google Scholar : PubMed/NCBI
18.	Wang FQ, Barfield E, Dutta S, Pua T and Fishman DA: VEGFR-2 silencing by interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol. 115:414–423. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Yen CF, Lee CL, Murk W, Han CM and Liao SK: Reducing peritoneal vascular endothelial growth factor concentration and inhibiting cancer scattering in a mouse model of laparoscopy. Am J Obstet Gynecol. 198:423.e1–423.e7. 2008.
20.	Yagi Y, Fushida S, Harada S, et al: Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol. 66:745–753. 2010. View Article : Google Scholar : PubMed/NCBI